Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaya Miah

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Pageof 2